Clinical trials and therapy.
Parallel-group studies have established the efficacy of cholinesterase inhibitors in Alzheimer's disease, at least for short-term cognitive and clinical global enhancement. Noncognitive outcomes are currently under scrutiny. Time to reach clinical milestones may be a more useful trial design for new studies aiming to delay appearance or progression of disease.
Gauthier
S
S
Department of Neurology and Neurosurgery, McGill University, Verdun, Quebec, Canada.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy; D006801:Humans; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors